Adefovir
Active ingredient
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
Overview
Plain-language summary, compiled from the cited regulatory records
Adefovir dipivoxil tablets are indicated for the treatment of chronic hepatitis B in patients 12 years of age and older [1]. This treatment is for individuals who show evidence of active viral replication and either persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease [1]. The indication is supported by data on histological, virological, biochemical, and serological responses observed in adult patients with both HBeAg-positive and HBeAg-negative chronic hepatitis B, who had compensated liver function [1].
Adefovir dipivoxil is available under various brand names [N]. The drug class for Adefovir is not specified in the provided data [N].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | July 22, 2025 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Adefovir dipivoxil tablets are indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function. Adefovir dipivoxil tablets are a nucleotide analogue indicated for the treatment of chronic hepatitis B in patients 12 years of age and older.
Sources & citations
- [1]FDA DailyMed · 08e07fae-3191-b6… · revised July 22, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.